Matches in SemOpenAlex for { <https://semopenalex.org/work/W89650042> ?p ?o ?g. }
Showing items 1 to 59 of
59
with 100 items per page.
- W89650042 abstract "Non-small cell lung cancer (NSCLC) accounts for about 85% of all lung cancer cases and is therefore one of the leading causes of cancer deaths worldwide. Afatinib is an oral receptor tyrosine kinase inhibitor (TKI) with antineoplastic activity which binds to and inhibits human epidermal growth factor receptors (EGFR). In September 2013, the European Medicines Agency (EMA) licensed afatinib for the treatment of EGFR TKI-naive adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutations. In July 2013, the US Food and Drug Administration (FDA) approved afatinib as first-line treatment of patients with metastatic NSCLC whose tumours have EGFR mutations. Two phase III studies (the LUX-Lung 3 and LUX-lung 6 trial) examined the efficacy and safety of afatinib as first-line therapy of EGFR TKI-naive patients with advanced or metastatic NSCLC with activating EGFR mutations. The trials compared treatment of patients either with afatinib or double-agent chemotherapy. For patients treated with afatinib, median PFS was extended by 4.2 months (HR 0.58, p=0.001) and 5.4 months respectively (HR 0.28, p<0.0001). Secondary endpoints including objective response rate and duration of response favoured patients treated with afatinib. Quality of life was also assessed, showing a significantly delayed time to deterioration for cough and dyspnoea in the afatinib group but conflicting results for pain. AEs were common in the afatinib and in the chemotherapy groups, but distinct differences in the toxicity profiles exist. Improvements in functional scales were observed for patients receiving afatinib compared with chemotherapy. Afatinib is the third EGFR TKI agent (besides erlotinib and gefitinib) licensed for the therapy of advanced NSCLC with EGFR mutations in Europe. Therefore, head-to-head comparison of afatinib, erlotinib and gefitinib is of great interest." @default.
- W89650042 created "2016-06-24" @default.
- W89650042 creator A5032291905 @default.
- W89650042 creator A5081312809 @default.
- W89650042 date "2013-11-01" @default.
- W89650042 modified "2023-09-27" @default.
- W89650042 title "Afatinib (Giotrif®) for the treatment of EGFR TKI-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s)" @default.
- W89650042 hasPublicationYear "2013" @default.
- W89650042 type Work @default.
- W89650042 sameAs 89650042 @default.
- W89650042 citedByCount "0" @default.
- W89650042 crossrefType "journal-article" @default.
- W89650042 hasAuthorship W89650042A5032291905 @default.
- W89650042 hasAuthorship W89650042A5081312809 @default.
- W89650042 hasConcept C121608353 @default.
- W89650042 hasConcept C126322002 @default.
- W89650042 hasConcept C143998085 @default.
- W89650042 hasConcept C2776256026 @default.
- W89650042 hasConcept C2776694085 @default.
- W89650042 hasConcept C2779438470 @default.
- W89650042 hasConcept C2780580887 @default.
- W89650042 hasConcept C2780586478 @default.
- W89650042 hasConcept C71924100 @default.
- W89650042 hasConceptScore W89650042C121608353 @default.
- W89650042 hasConceptScore W89650042C126322002 @default.
- W89650042 hasConceptScore W89650042C143998085 @default.
- W89650042 hasConceptScore W89650042C2776256026 @default.
- W89650042 hasConceptScore W89650042C2776694085 @default.
- W89650042 hasConceptScore W89650042C2779438470 @default.
- W89650042 hasConceptScore W89650042C2780580887 @default.
- W89650042 hasConceptScore W89650042C2780586478 @default.
- W89650042 hasConceptScore W89650042C71924100 @default.
- W89650042 hasLocation W896500421 @default.
- W89650042 hasOpenAccess W89650042 @default.
- W89650042 hasPrimaryLocation W896500421 @default.
- W89650042 hasRelatedWork W1988976748 @default.
- W89650042 hasRelatedWork W2004915982 @default.
- W89650042 hasRelatedWork W2032712631 @default.
- W89650042 hasRelatedWork W2072084159 @default.
- W89650042 hasRelatedWork W2079118069 @default.
- W89650042 hasRelatedWork W2518851971 @default.
- W89650042 hasRelatedWork W2549473871 @default.
- W89650042 hasRelatedWork W2580989324 @default.
- W89650042 hasRelatedWork W2728181306 @default.
- W89650042 hasRelatedWork W2768972745 @default.
- W89650042 hasRelatedWork W2891350774 @default.
- W89650042 hasRelatedWork W2894935483 @default.
- W89650042 hasRelatedWork W2906574801 @default.
- W89650042 hasRelatedWork W2947113393 @default.
- W89650042 hasRelatedWork W2979930936 @default.
- W89650042 hasRelatedWork W3036183865 @default.
- W89650042 hasRelatedWork W3085153121 @default.
- W89650042 hasRelatedWork W3134073672 @default.
- W89650042 hasRelatedWork W3177774675 @default.
- W89650042 hasRelatedWork W2753213968 @default.
- W89650042 isParatext "false" @default.
- W89650042 isRetracted "false" @default.
- W89650042 magId "89650042" @default.
- W89650042 workType "article" @default.